 |
|
Cardiovascular Outcomes in Trials of Oral Diabetes MedicationsA Systematic Review
Elizabeth Selvin, PhD, MPH;
Shari Bolen, MD, MPH;
Hsin-Chieh Yeh, PhD;
Crystal Wiley, MD, MPH;
Lisa M. Wilson, ScM;
Spyridon S. Marinopoulos, MD, MBA;
Leonard Feldman, MD;
Jason Vassy, MD, MPH;
Renee Wilson, MS;
Eric B. Bass, MD, MPH;
Frederick L. Brancati, MD, MHS
Arch Intern Med. 2008;168(19):2070-2080.
Background A wide variety of oral diabetes medications are currently available for the treatment of type 2 diabetes mellitus, but it is unclear how these agents compare with respect to long-term cardiovascular risk. Our objective was to systematically examine the peer-reviewed literature on the cardiovascular risk associated with oral agents (second-generation sulfonylureas, biguanides, thiazolidinediones, and meglitinides) for treating adults with type 2 diabetes.
Methods We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, from inception through January 19, 2006. Forty publications of controlled trials that reported information on cardiovascular events (primarily myocardial infarction and stroke) met our inclusion criteria. Using standardized protocols, 2 reviewers serially abstracted data from each article. Trials were first described qualitatively. For comparisons with 4 or more independent trials, results were pooled quantitatively using the Mantel-Haenszel method. Results are presented as odds ratios (ORs) and corresponding 95% confidence intervals (CIs).
Results Treatment with metformin hydrochloride was associated with a decreased risk of cardiovascular mortality (pooled OR, 0.74; 95% CI, 0.62-0.89) compared with any other oral diabetes agent or placebo; the results for cardiovascular morbidity and all-cause mortality were similar but not statistically significant. No other significant associations of oral diabetes agents with fatal or nonfatal cardiovascular disease or all-cause mortality were observed. When compared with any other agent or placebo, rosiglitazone was the only diabetes agent associated with an increased risk of cardiovascular morbidity or mortality, but this result was not statistically significant (OR, 1.68; 95% CI, 0.92-3.06).
Conclusions Meta-analysis suggested that, compared with other oral diabetes agents and placebo, metformin was moderately protective and rosiglitazone possibly harmful, but lack of power prohibited firmer conclusions. Larger, long-term studies taken to hard end points and better reporting of cardiovascular events in short-term studies will be required to draw firm conclusions about major clinical benefits and risks related to oral diabetes agents.
Author Affiliations: Departments of Epidemiology (Drs Selvin, Yeh, and Brancati) and Health Policy and Management (Dr Bass), Johns Hopkins Bloomberg School of Public Health, The Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions (Drs Selvin, Yeh, and Brancati), Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine (Drs Bolen, Yeh, Wiley, Marinopoulos, Feldman, Bass, and Brancati and Mss L. M. Wilson and R. Wilson), and John Hopkins Evidence-Based Practice Center, The Johns Hopkins University (Mss L. M. Wilson and R. Wilson and Dr Bass), Baltimore, Maryland; and Department of Medicine, Washington University School of Medicine, St Louis, Missouri (Dr Vassy).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
In This Issue of Archives of Internal Medicine
Arch Intern Med. 2008;168(19):2063.
FULL TEXT
Glycemic Management of Type 2 Diabetes: How Tight Is Right and How to Get There
David M. Nathan
Arch Intern Med. 2008;168(19):2064-2066.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas
Naka et al.
Diabetes and Vascular Disease Research 2012;9:52-58.
ABSTRACT
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation Endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association
Smith et al.
J Am Coll Cardiol 2011;58:2432-2446.
FULL TEXT
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation
Smith et al.
Circulation 2011;124:2458-2473.
FULL TEXT
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
Schramm et al.
Eur Heart J 2011;32:1900-1908.
ABSTRACT
| FULL TEXT
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
Boussageon et al.
BMJ 2011;343:d4169-d4169.
ABSTRACT
| FULL TEXT
Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
Bennett et al.
ANN INTERN MED 2011;154:602-613.
ABSTRACT
| FULL TEXT
Diabetes: a driver for heart failure
Voors and van der Horst
Heart 2011;97:774-780.
FULL TEXT
Diabetes Treatment and Cardiovascular Safety
Bloomgarden
Diabetes Care 2011;34:e36-e42.
FULL TEXT
What have we learnt from the rosiglitazone saga?
Montori and Shah
BMJ 2011;342:d1354-d1354.
FULL TEXT
Database Evaluation of the Effects of Long-Term Rosiglitazone Treatment on Cardiovascular Outcomes in Patients With Type 2 Diabetes
Loebstein et al.
J Clin Pharmacol 2011;51:173-180.
ABSTRACT
| FULL TEXT
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi et al.
Cancer Prev Res 2010;3:1451-1461.
ABSTRACT
| FULL TEXT
The Association of Hemoglobin A1c With Incident Heart Failure Among People Without Diabetes: The Atherosclerosis Risk in Communities Study
Matsushita et al.
Diabetes 2010;59:2020-2026.
ABSTRACT
| FULL TEXT
Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case-Control Study From the U.K. General Practice Research Database
MacDonald et al.
Diabetes Care 2010;33:1213-1218.
ABSTRACT
| FULL TEXT
Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No
Kassem and Raz
Diabetes Care 2009;32:S337-S341.
FULL TEXT
Glycemic Control in Type 2 Diabetes: Time for an Evidence-Based About-Face?
Montori and Fernandez-Balsells
ANN INTERN MED 2009;150:803-808.
ABSTRACT
| FULL TEXT
Therapy for Alzheimer's Disease: How Effective are Current Treatments?
Lanctot et al.
Therapeutic Advances in Neurological Disorders 2009;2:163-180.
ABSTRACT
Tight control of blood glucose in long standing type 2 diabetes
Lehman and Krumholz
BMJ 2009;338:b800-b800.
FULL TEXT
Meta-Analysis of Oral Agents for Diabetes Shows Weakness of the Literature
Journal Watch Cardiology 2008;2008:4-4.
FULL TEXT
All you need to read in the other general journals
BMJ 2008;337:a2391-a2391.
FULL TEXT
Glycemic Management of Type 2 Diabetes: How Tight Is Right and How to Get There
Nathan
Arch Intern Med 2008;168:2064-2066.
FULL TEXT
|
